Immune Checkpoint Inhibitors Market Estimated to Exceed US$ 30,000 Mn by 2026-end| Competition Tracking: AstraZeneca, Bristol-Myers Squibb, Celldex Therapeutics, F. Hoffman-La Roche, Incyte Corporation, Merck & Co., Inc., Merck KGaA

Immune checkpoint inhibitors are drugs or drug candidates, which block/inhibit the inhibitory checkpoint molecules, often referred to as checkpoint blockade. Immune checkpoint inhibitors are used for treatment of various types of cancers including melanoma, lung cancer, blood cancer, renal cell carcinoma, squamous cell carcinoma, urothelial carcinoma, and colorectal cancer.

Request Sample Report @ https://www.mrrse.com/sample/4174

Immune checkpoint inhibitors have been hailed by oncologists as one of the major breakthroughs for treatment of cancer, with impressive long-lasting and durable responses. Cancer-affected patients have been provided with extended years of life following treatment with immune checkpoint inhibitors. These drugs have been deemed quite successful in treating patients with metastatic cancer, especially lung cancer and melanoma. Here, these drugs have transformed the once referred as fatal diseases into chronic conditions. Immune checkpoint inhibitors are considered to have immense potential in treating renal cell carcinoma, and urothelial cancer.

The U.S. Food and Drug Administration (FDA) has recently approved five immune checkpoint inhibitor drugs viz. ipilimumab (Yervoy®), nivolumab (Opdivo®), pembrolizumab (Keytruda®), avelumab (Bavencio®), and atezolizumab (Tecentriq®). In addition, various clinical trials on immune checkpoint inhibitor drugs for a wide range of conditions are being carried out by leading drug manufacturers. A major issue witnessed in employing immune checkpoint inhibitors is their effectiveness for only a few types of cancers, owing to the cancer cells’ property of inhibiting pathways affecting T cell functions. Scientists are therefore commencing to address the issue through different drug combinations, and developing treatment methods that target immune-evasion mechanisms.

The global immune checkpoint inhibitors market is projected to ride on a high double-digit CAGR during the forecast period (2017-2026), according to a new research study. Revenues from the market are estimated to exceed US$ 30,000 Mn by 2026-end.

On the basis of drug class, PD-1 inhibitors are expected to remain sought-after in the market, with sales poised to exceed US$ 20,000 Mn by 2026-end. PD-1 inhibitors have replaced the existing radiotherapy and chemotherapy procedures for cancer therapeutics. In addition, numerous clinical trials are being carried out for combination therapy regarding PD-1 inhibitors across the globe. Revenue share of PD-1 inhibitors will remain considerably larger than all the other drug class available in the market during the forecast period.

Access Complete Report with Table of Content @ https://www.mrrse.com/immune-checkpoint-inhibitors-market

Immune checkpoint inhibitors will continue to witness the largest therapeutic application in lung cancer, followed by melanoma. Revenues from these two therapeutic applications of immune checkpoint inhibitors are projected to account for over half share of the market in 2017. Demand for immune checkpoint inhibitors in treating lung cancer will register a significant decline, while demand in treating melanoma will gain a slight uptick by 2026-end.

Specialty pharmacies are projected to be the fastest expanding distribution channel for immune checkpoint inhibitors during the forecast period, however revenues from specialty pharmacies will remain relatively lower than all the other distribution channels in the market. Retail pharmacies are expected to account for a comparatively larger revenue share of the market than specialty pharmacies by 2026-end.

Dominance of North America in the global immune checkpoint inhibitors market is anticipated to remain unchallenged. The region is projected to account for over two-third share of the market during 2017 to 2026, in terms of revenues. The market in Europe will register a comparatively higher CAGR than that in North America, to become the second most lucrative market for immune checkpoint inhibitors by 2026-end.

Key companies profiled by PMR in its report include AstraZeneca, Bristol-Myers Squibb, Celldex Therapeutics, F. Hoffman-La Roche, Incyte Corporation, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi, Mirada Medical Limited, Sciencesoft USA Corporation, Siemens Healthineers, Toshiba Medical Systems Corporation, and Xinapse Systems Ltd.

Enquire about this Report @ https://www.mrrse.com/enquiry/4174

About Us

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact

State Tower
90, State Street
Suite 700
Albany, NY – 12207
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com
Website: https://www.mrrse.com/

This release was published on openPR.